Fresh from the No­var­tis/Trump scan­dal, ex-CEO Joe Jimenez jumps on the board of uBio­me — a biotech launch­ing an R&D group

Af­ter fig­ur­ing in as one of the cen­tral fig­ures for one of the most talked about scan­dals in bio­phar­ma his­to­ry, ex-No­var­tis CEO Joe Jimenez is step­ping back out on­to the stage to­day with a board seat at a com­mer­cial mi­cro­bio­me com­pa­ny that is now set­ting its sights on cre­at­ing a drug de­vel­op­ment arm.

Launched 6 years ago from its base in the Bay Area, uBio­me has launched a pair of con­sumer tests that can do at-home tests on your gut or the STDs that women face, like chlamy­dia and gon­or­rhea. Now the com­pa­ny has raised $83 mil­lion from ven­ture back­ers — led by OS Fund — in a new dri­ve to join the pack de­vel­op­ing new mi­cro­bio­me ther­a­pies. That’s been a fast-grow­ing field in re­cent times.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER